Metabolic surgery significantly lowered risk for major adverse liver outcomes vs. nonsurgical management among patients with obesity and compensated cirrhosis from metabolic dysfunction-associated ...
Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity ...
Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...
Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...
We recently compiled a list of the Jim Cramer Discusses These 12 Stocks, Elon Musk & President Trump. In this article, we are ...
The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...
Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:48 a.m. ET, incorrectly said his ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...
The data highlight the possibility of SGLT 1/2 inhibitors having protective effects beyond heart failure and diabetes.
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...